EMEND® (SUSPENSION)

Drug Information Related Patent

Hold Company

MERCK SHARP DOHME

Learn More

Dosage and Administration

FOR SUSPENSION;ORAL

Specification

125MG/KIT

Indication

EMEND® is indicated for patients 6 months and older for the prevention of: acute and delayed nausea and vomiting associated with initial and repeat courses of hyperemetogenic cancer chemotherapy (HEC) including high-dose cisplatin, and nausea and vomiting associated with MEC.

Use

Instructions for Use

API

APREPITANT

API Structure